Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
09/2005
09/15/2005US20050202415 Coronavirus amino acid sequences for use in prevention and treatment of infection and cell proliferative disorders
09/15/2005US20050202413 nucleic acid encoding an immunoreactive peptide not recognized by antibodies which are directed against other herpes-viruses for accurate diagnosis; test kits
09/15/2005US20050202048 Chlamydia antigens and vaccine uses of the protein
09/15/2005US20050202028 Binding domain-immunoglobulin fusion proteins
09/15/2005US20050202026 Introducing into a first plant an expression vector containing a nucleotide sequence encoding the protection protein operably linked to a transcriptional promoter, introducing into a second plant an expression vector, crossing first plant and second plant to produce offspring, selecting transgenic plant
09/15/2005US20050202025 Antibodies to the FbsA protein of streptococcus agalactiae and their use in treating or preventing infections
09/15/2005US20050202024 Protein sequences containing antigenized antibodies for foot-and-mouth disease
09/15/2005US20050202023 Use of molecularly engineered binding domain-immunoglobulin fusion proteins, including single chain Fv-immunoglobulin fusion protein useful for treating malignant conditions and B-cell disorders, such as disease caused by autoantibody production
09/15/2005US20050202022 Polynucleotides encoding humanized antibodies against human 4-1BB
09/15/2005US20050202021 Anti-cancer antibodies with reduced complement fixation
09/15/2005US20050202020 Diagnosing and treating cancer
09/15/2005US20050202019 Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
09/15/2005US20050202018 Binding agent, conjugated to a keyhole limpet hemocyanin, that specifically binds to circulating prostate specific antigen and induces a therapeutic immune response
09/15/2005US20050202017 Assay; contacting a test compound with a HB-954 polypeptide; determining whether the test compound binds to the G protein-coupled receptor
09/15/2005US20050202016 Polypeptide; an amino acid sequence of the family of tumour-suppressing genes related to the gene for the p53 protein; isolated nucleic acid sequences coding for the proteins
09/15/2005US20050202015 Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
09/15/2005US20050202014 Methods of blocking tissue destruction by autoreactive T cells
09/15/2005US20050202013 Novel Th2-specific molecules and uses thereof
09/15/2005US20050202012 Binding domain-immunogloubulin fusion proteins
09/15/2005US20050202011 Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith
09/15/2005US20050202010 Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
09/15/2005US20050202009 Novel MHC II associated peptides
09/15/2005US20050202003 Methods for sterilizing preparations of monoclonal immunoglobulins
09/15/2005US20050201994 Administering a human sequence antibody that specifically binds to human Cytotoxic T-lymphocyte-associated protein 4; anticarcinogenic, antitumor
09/15/2005US20050201979 Reduced vasopermeability activity and similar binding affinity for an IL-2 receptor compared to its wildtype form; immunostimulants; immuotherapy; anticarcinogenic agents; renal cell cancer, melanoma; chemotherapy and/or radiation therapy; viricides; human immunodeficiency virus; autoimmune disorders
09/15/2005US20050201973 Therapeutic supramolecules
09/15/2005US20050201938 Method for selectively inhibiting ghrelin action
09/15/2005US20050201932 Drug delivery using Polymeric immunoglobulin receptor (pIgR) which when cleaved has a stalk region which remains attached to the cell and a secretory component (SC) which exists in an organ of interest in several forms
09/15/2005DE102004007462A1 Antikörper sowie Verfahren zur Diagnose und Behandlung von Schizophrenie Antibodies, and methods for diagnosis and treatment of schizophrenia
09/15/2005CA2812132A1 Natural igm antibodies and inhibitors thereof
09/15/2005CA2560066A1 Natural igm antibodies and inhibitors thereof
09/15/2005CA2558813A1 Pharmaceutical composition comprising cxcr3 inhibitor
09/15/2005CA2558596A1 Anti fk778 antibodies and high sensitive immunoassay methods
09/15/2005CA2558399A1 Partially loaded antibodies and methods of their conjugation
09/15/2005CA2557788A1 Mutein of a bone morphogenetic protein and use thereof
09/15/2005CA2552420A1 Method of assessing rheumatoid arthritis by measuring anti-ccp and serum amyloid a
09/14/2005EP1574579A2 Outer surface proteins, their genes, and their use
09/14/2005EP1574577A2 Growth differentiation factor-11
09/14/2005EP1574519A1 Transcription control factor ZHX3
09/14/2005EP1574517A1 HCV E1 comprising specific disulfide bridges
09/14/2005EP1573323A2 Prion protein ligands and methods of use
09/14/2005EP1573048A2 Breast specific protein expressed in cancer and methods of use thereof
09/14/2005EP1573035A2 Brother of the regulator of imprinted sites (boris)
09/14/2005EP1573031A2 Androgen regulated nucleic acid molecules and encoded proteins
09/14/2005EP1573029A2 Modulation of immune-cell related disorders using il-1hy2
09/14/2005EP1573028A2 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
09/14/2005EP1573024A2 Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
09/14/2005EP1573023A2 Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer
09/14/2005EP1573022A2 Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer
09/14/2005EP1573002A2 Antibody variants with faster antigen association rates
09/14/2005EP1572995A2 Novel proteins and nucleic acids encoding same
09/14/2005EP1572976A2 Modulating immune responses
09/14/2005EP1572972A2 Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
09/14/2005EP1572971A2 Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
09/14/2005EP1572967A2 Il-1 receptor based antagonists and methods of making and using
09/14/2005EP1572965A2 Human sarcoma-associated antigens
09/14/2005EP1572955A2 Antibodies against c3a receptor
09/14/2005EP1572951A2 Nucleotide sequences that code for torsin genes, torsin proteins, and methods of using the same to treat protein-aggregation
09/14/2005EP1572946A2 Therapeutic human anti-il-1r1 monoclonal antibody
09/14/2005EP1572939A2 Her-2 receptor tyrosine kinase molecules and uses thereof
09/14/2005EP1572938A2 Polyvalent cation-sensing receptor in atlantic salmon
09/14/2005EP1572937A2 Motif-grafted hybrid polypeptides and uses thereof
09/14/2005EP1572935A2 Methods of making hypermutable cells using pmsr homologs
09/14/2005EP1572931A2 Methods and compositions for modulating and detecting wisp activity
09/14/2005EP1572924A2 Contraceptive targets
09/14/2005EP1572917A2 Antibody gene transfer and recombinant aav therefor
09/14/2005EP1572916A2 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
09/14/2005EP1572913A2 Methods for the identification of novel ligands for the g protein-coupled receptor (gpcr) 192
09/14/2005EP1572909A2 A follistatin domain containing protein
09/14/2005EP1572905A2 Cancer-linked gene as target for chemotherapy
09/14/2005EP1572903A2 Immunotherapeutics for biodefense
09/14/2005EP1572900A2 Antibodies directed to pdgfd and uses thereof
09/14/2005EP1572898A2 Novel proteins and nucleic acids encoding same
09/14/2005EP1572890A2 Slc7s as modifies of the p53 pathway and methods of use
09/14/2005EP1572883A2 Human cytokine receptor
09/14/2005EP1572881A2 Tacis and br3 polypeptides and uses thereof
09/14/2005EP1572877A2 Drug metabolizing enzymes
09/14/2005EP1572875A2 Receptors and membrane-associated proteins
09/14/2005EP1572874A2 Antibodies that immunospecifically bind to trail receptors
09/14/2005EP1572872A2 Igs as modifiers of the p53 pathway and methods of use
09/14/2005EP1572871A2 T1r3 a novel taste receptor
09/14/2005EP1572868A2 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
09/14/2005EP1572867A2 Endothelial cell expression patterns
09/14/2005EP1572864A2 Human serpin polypeptides
09/14/2005EP1572861A2 Ap1 amine oxidase variants
09/14/2005EP1572748A1 Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
09/14/2005EP1572747A2 Tumor-specific recognition molecules
09/14/2005EP1572746A2 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
09/14/2005EP1572745A2 Antibody ("11c7") anti nogo a and its pharmaceutical use
09/14/2005EP1572744A2 Immunoglobulin variants and uses thereof
09/14/2005EP1572742A2 Immunogenic compositions to the cck-b/gastrin receptor and methods for the treatment of tumors
09/14/2005EP1572741A1 Therapeutic and diagnostic agents
09/14/2005EP1572739A1 Asthma susceptibility locus
09/14/2005EP1572730A2 Nact as a target for lifespan expansion and weight reduction
09/14/2005EP1572721A2 Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
09/14/2005EP1572720A2 Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
09/14/2005EP1572718A2 Alpha nu beta 3 integrin-binding polypeptide monobodies and their use
09/14/2005EP1572224A2 Methods and compositions for inhibiting binding of ige to a high affinity receptor
09/14/2005EP1572169A2 Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof
09/14/2005EP1572149A2 Immunogenicity of glucan binding protein
1 ... 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 ... 1494